Valenyx Therapeutics is developing multispecific nanobody-based biologics for complex diseases, starting with osimertinib-resistant non-small cell lung cancer. Its platform combines proteomics-based discovery of serum-matured nanobodies with machine-learning candidate ranking and epitope-first engineering. [1]
The modular nanobody formats can be assembled into degrader-drug conjugates, T-cell engagers, antibody-oligonucleotide conjugates, and brain-shuttle biologics. The lead program, VT-001, is a tri-specific degrader-drug conjugate for non-small cell lung cancer and other solid tumors and is in IND-enabling studies. VT-002, a tri-specific dual-degrader conjugate, is in preclinical development, and VT-003, a broad-tissue single-domain antibody for CNS and muscle disease, is in discovery. [1]
The company is based in New York and is co-founded by CEO Md Kabir and scientific co-founders Jian Jin and Yi Shi, whose research on multispecific nanobody degraders underpins the platform. [2]